• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Genmab A/S ADR (NQ: GMAB )

    28.24 -0.11 (-0.39%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Genmab A/S ADR

    < Previous 1 2 3 4 5 6 Next >
    What 8 Analyst Ratings Have To Say About Genmab
    Via Benzinga
    What 8 Analyst Ratings Have To Say About Genmab
    Via Benzinga
    Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably. 
    Via Chartmill
    NASDAQ:GMAB, an undervalued stock with good fundamentals.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
    Via Chartmill
    AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
    The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. 
    Via Benzinga
    Exposures Product Safety
    7 Biotech Stocks to Buy on the Dip: June 2024
    With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
    Via InvestorPlace
    10 Analysts Assess Genmab: What You Need To Know
    Via Benzinga
    What 9 Analyst Ratings Have To Say About Genmab
    Via Benzinga
    NASDAQ:GMAB is showing good growth, while it is not too expensive.
    Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB). 
    Via Chartmill
    Despite its growth, NASDAQ:GMAB remains within the realm of affordability.
    Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. 
    Via Chartmill
    7 Stocks That Could Safely 10X by 2030
    Unlock the potential for exponential growth with these seven 10x stocks that could skyrocket by 2030 if the stars align. 
    Via InvestorPlace
    Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
    Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
    Via InvestorPlace
    GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024
    GMAB stock results show that Genmab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Decoding 9 Analyst Evaluations For Genmab
    Via Benzinga
    NASDAQ:GMAB is not too expensive for the growth it is showing.
    Via Chartmill
    Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
    Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout. 
    Via Chartmill
    Analyst Ratings For Genmab
    Via Benzinga
    Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
    The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
    Via Investor's Business Daily
    ProfoundBio Discovers The Joys Of Having A Wealthy Owner
    Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a... 
    Via Benzinga
    Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
    ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
    Via Talk Markets
    Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio
    Genmab is buying a privately held company focused on antibody drug conjugates. 
    Via Investor's Business Daily
    NASDAQ:GMAB is showing good growth, while it is not too expensive.
    For those who appreciate growth without the sticker shock, GENMAB A/S -SP ADR (NASDAQ:GMAB) is worth considering. 
    Via Chartmill
    4 Analysts Assess Genmab: What You Need To Know
    Via Benzinga
    Earnings Outlook For Genmab
    Via Benzinga
    NASDAQ:GMAB, a strong growth stock, setting up for a breakout.
    Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock? 
    Via Chartmill
    Why NASDAQ:GMAB Is a Promising High-Growth Stock in the Midst of Consolidation.
    Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. 
    Via Chartmill
    NASDAQ:GMAB is showing good growth, while it is not too expensive.
    While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable. 
    Via Chartmill
    Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
    While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable. 
    Via Chartmill
    Cracking The Code: Understanding Analyst Reviews For Genmab
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.